Printer Friendly

The US FDA issues consent decree of permanent injunction against Ben Venue Laboratories.

M2 PHARMA-February 5, 2013-The US FDA issues consent decree of permanent injunction against Ben Venue Laboratories(C)2013 M2 COMMUNICATIONS

The US Food and Drug Administration (FDA) has stated that the federal judge has issued a consent decree of permanent injunction against Ben Venue Laboratories, a subsidiary of Boehringer Ingelheim, and three of its corporate officers, it was reported yesterday.

The consent decree of permanent injunction has been issued for failing to meet with present good manufacturing practice requirements as required by federal law.

The decree was signed by the US District Court for the Northern District judge Lesley Wells of Ohio on 31 January 2013, and was issued to the company's chief executive officer, vice president of operations and vice president of quality operations.

((Comments on this story may be sent to info@m2.com)).END.PUB430>PDFebruary 5, 2013>JNM2 PHARMA.PRICEDATENOT APPLICABLE.DAY

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 5, 2013
Words:146
Previous Article:Cerulean Pharma doses first patient in Phase 2 study of CRLX101 drug.
Next Article:MDH Radiology signs contract with Sectra.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters